18th Sep 2015 16:39
For immediate release | 18 September 2015 |
ABCAM PLC
("Abcam" or "the Company")
Director/PDMR Dealings
Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, announces that it was notified on 18 September 2015 of the following transactions in Abcam's shares on that date by certain Directors and PDMRs of the Company:
· Murray Hennessy, Chairman, purchased 8,175 Ordinary Shares of 0.2 pence each in the Company ("Ordinary Shares") at a price of 612.0 pence per share. Following this transaction, Mr Hennessy's total interest in the Company has increased by 8,175 Ordinary Shares to a total of 26,975 Ordinary Shares, representing approximately 0.01% of the Company's issued share capital.
· Alan Hirzel, CEO, purchased 4,000 Ordinary Shares at a price of 614.9 pence per share. Following this transaction, Mr Hirzel's total interest in the Company has increased by 4,000 Ordinary Shares to a total of 23,205 Ordinary Shares, representing approximately 0.01% of the Company's issued share capital.
· Louise Patten, Senior Independent Director, purchased 5,000 Ordinary Shares at a price of 615.5 pence per share. Following this transaction, Lady Patten's total interest in the Company has increased by 5,000 Ordinary Shares to a total of 24,883 Ordinary Shares, representing approximately 0.01% of the Company's issued share capital.
· Suzanne Smith, Chief Legal Officer and Company Secretary (PDMR), purchased 1,611 Ordinary Shares at a price of 616.6 pence per share. Following this transaction, Mrs Smith's total interest in the Company has increased by 1,611 Ordinary Shares to a total of 1,611 Ordinary Shares, representing approximately 0.001% of the Company's issued share capital.
For further information please contact:
Abcam | + 44 (0) 1223 696 000 |
Alan Hirzel, Chief Executive Officer Jeff Iliffe, Chief Financial Officer Laura Taylor, Investor Relations Manager | |
J.P.Morgan Cazenove - Nominated Adviser & Joint Corporate Broker | + 44 (0) 20 7742 4000 |
James Mitford / Alex Bruce - Nominated Adviser | |
Peel Hunt LLP - Joint Corporate Broker | + 44 (0) 20 7418 8900 |
James Steel / Jock Maxwell MacDonald - Corporate Broking | |
FTI Consulting | +44 (0) 20 3727 1000 |
Ben Atwell / Brett Pollard / Natalie Garland-Collins |
Notes to Editors
About Abcam
Abcam plc is a provider of life science research tools, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.
Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company's catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.
Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices enabling local services, multi-language support and next-day delivery in over 130 countries. The Company was founded in 1998, and now employs over 820 people. Abcam was admitted to AIM in 2005 (AIM:ABC).
To find out more, please visit www.abcam.com
Related Shares:
ABC.L